



Correction to: Sodium Oligomannate: First Approval

Yahiya Y. Syed¹

Published online: 24 February 2020
© Springer Nature Switzerland AG 2020

Correction to: Drugs (2020)
<https://doi.org/10.1007/s40265-020-01268-1>

Section 1. Introduction

The second sentence in paragraph 3, which currently reads “The full approval requires additional data on the drugs mechanism of action and long-term efficacy and safety [7, 9].”

Should read: “The full approval required additional data [7, 9] from a 2-year carcinogenicity study in rats [8]. This study has been completed and data were submitted to the China CDE in January 2020.”

Section 2.1. Pharmacodynamics

The first sentence, which currently reads: “Sodium oligomannate is produced by depolymerizing propylene glycol alginate sodium sulfate followed by oxidation, leaving carboxyl group at the reduced end [11].”

Should read: “Sodium oligomannate is produced by depolymerizing alginate and subsequent oxidation to oligosaccharides [11].”

The last sentence of paragraph 3, which currently reads: “In the phase II trial, sodium oligomannate treatment was associated with an increase in $A\beta_{1-42}$ levels in the cerebrospinal fluid (CSF), suggesting clearance of amyloid from the brain into the CSF [13].”

Should read “In a small ($n = 13$) phase IIa pilot study, sodium oligomannate treatment was associated with an increase in $A\beta_{1-42}$ levels in the cerebrospinal fluid (CSF), suggesting clearance of amyloid from the brain into the CSF [13].”

Section 2.2 Pharmacokinetics

The second sentence of the first paragraph: the units for AUC_{∞} should be ng·h/mL.

Section 2.3 Therapeutic Trials.

In the first paragraph, third sentence, which currently reads: “In the full analysis set ($n = 678$), the primary...”

Should read: “In patients who completed the study ($n = 678$), the primary...”

Features and properties of sodium oligomannate table

The mechanism of action line, which currently reads: “Amino acid modulators; Amyloid beta-protein inhibitors; Microbiome modulators”

Should read: “Neuroinflammation modulators; Amyloid beta-protein inhibitors; Microbiome modulators”

The chemical name, which currently reads: “Oligo-B-1 → 4-D-mannuronic acid sodium dibasic acid”


Should read: “Sodium oligo- β -1 → 4-D-mannuronic acid-*O*-dicarboxylic acid”

The original article can be found online at <https://doi.org/10.1007/s40265-020-01268-1>.

✉ Yahiya Y. Syed
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

Key milestone figure. This has been amended to indicate that Phase I trials were initiated in 2007 and that Phase I trials initiated in 2016 included a higher dose.



The original article has been corrected.